Evidence map›Paper›PMID 40806543›Full record

ArticleInternational journal of molecular sciences2025

Comparative Evaluation of ARB Monotherapy and SGLT2/ACE Inhibitor Combination Therapy in the Renal Function of Diabetes Mellitus Patients: A Retrospective, Longitudinal Cohort Study.

Andrew W Ngai, Aqsa Baig, Muhammad Zia, Karen Arca-Contreras, Nadeem Ul Haque, Veronica Livetsky, Marcelina Rokicki, Shiryn D Sukhram

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrew W NgaiDepartment of Biology, College of Staten Island, City University of New York, 2800 Victory Boulevard, Building 6S, Staten Island, NY 10314, USA.
Aqsa BaigDepartment of Environmental and Public Health Sciences, University of Cincinnati, 160 Panzeca Way, Kettering Lab Building, Cincinnati, OH 45267, USA.
Muhammad ZiaDepartment of Biology, College of Staten Island, City University of New York, 2800 Victory Boulevard, Building 6S, Staten Island, NY 10314, USA.ORCID 0009-0002-0762-4118
Karen Arca-ContrerasNursing Department, College of Staten Island, City University of New York, 2800 Victory Boulevard, Building 5S, Staten Island, NY 10314, USA.
Nadeem Ul HaqueAZZ Medical Associates, 631 Broadway, Suite 2, Bayonne, NJ 07002, USA.
Veronica LivetskyDepartment of Biology, College of Staten Island, City University of New York, 2800 Victory Boulevard, Building 6S, Staten Island, NY 10314, USA.
Marcelina RokickiDepartment of Biology, College of Staten Island, City University of New York, 2800 Victory Boulevard, Building 6S, Staten Island, NY 10314, USA.
Shiryn D SukhramDepartment of Biology, College of Staten Island, City University of New York, 2800 Victory Boulevard, Building 6S, Staten Island, NY 10314, USA.ORCID 0000-0001-7314-5487

Funding

City University of New York Cycle 54, Award number 66178-00 54.
6 · The paper itself

Abstract

Diabetic nephropathy affects approximately 30-40% of individuals with diabetes mellitus (DM) and is a major contributor to end-stage renal disease (ESRD). While angiotensin II receptor blockers (ARBs) have long served as a standard treatment, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have recently gained attention for their renal and cardiovascular benefits. However, comparative real-world data on their long-term renal effectiveness remain limited. We conducted a retrospective, longitudinal study over a 2-year period to compare the impact of ARB monotherapy versus SGLT2i and angiotensin-converting enzyme inhibitor (ACEi) combination therapy on the progression of chronic kidney disease (CKD) in patients with DM. A total of 126 patients were included and grouped based on treatment regimen. Renal biomarkers were analyzed using

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsDiabetes Mellitus, Type 2Diabetic NephropathiesSodium-Glucose Transporter 2 InhibitorsAgedAlbuminuriaBiomarkersCreatinineDrug Therapy, CombinationFemaleGlomerular Filtration RateGlycated HemoglobinHumansKidneyLongitudinal StudiesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBiomarkersCreatinineGlycated HemoglobinSodium-Glucose Transporter 2 Inhibitorsangiotensin-converting enzyme inhibitorsangiotensin II receptor blockerschronic kidney diseasediabetic kidney diseasediabetic nephropathysodium-glucose cotransporter-2 inhibitors

Identifiers

PMID40806543
PMCPMC12347022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.